We established a diversified and comprehensive R&D pipeline covering oncology, autoimmune diseases, pain management, cardiovascular diseases, metabolic diseases, infectious diseases, respiratory system diseases, hematological diseases, neurological diseases, ophthalmology, etc.
27
New Molecular Entity drugs marketed in China
6
Other innovative drugs marketed in China
100
In-House Innovative Pharmaceuticals under Clinical Development
400
Ongoing Clinical Studies
20
Ongoing International Clinical Studies
*By Jul,2026
EGPA (eosinophilic granulomatosis with polyangiitis); HoFH (homozygous familial hypercholesterolemia); Nr-axSpA (non-radiographic axial spondyloarthritis); mCRPC (metastatic castration-resistant prostate cancer).
Notes: (1) US, Europe (2) US, Europe; (3) Europe; (4) US, Europe, Asia-Pacific (including China).
Neo/adj (neoadjuvant/adjuvant), r/r (relapsed/refractory); mHNSCC (metastatic head and neck squamous cell carcinoma), NMIBC (non-muscle invasive bladder cancer), OC (ovarian cancer), HTG (hypertriglyceridemia), VTE (venous thromboembolism), IPF (Idiopathic pulmonary fibrosis).
Notes: (1) Combo with adebrelimab; (2) Combo with adebrelimab + SHR-8068; (3) US; (4) Mono / Combo; (5) US, Europe